Thus, we hypothesize that many TNFR2+Tregs have undergone trafficking to the in situ tumor microenvironment from peripheral circulation as the carcinoma progressed, leading to a decrease in the circulating subsets. The gene discussed is TNFRSF1B; the disease is carcinoma.